ResTORbio announces human trials for RTB101, a mTOR-targeting therapy.

ResTORbio Announces Phase 3 Human Trials

resTORbio released positive results from its phase 2b trial in humans, which was aimed at aging immune systems with an immune-boosting drug. After a successful negotiation with FDA, resTORbio has now announced that the therapy will be moving into a phase 3-study later this year.

Targeting mTOR as a pathway for aging

ResTORbio, a biopharmaceutical firm, develops therapies that target the aging process in order to cure or prevent age-related illnesses. RTB101 is its primary candidate drug, and it targets a part of the mTOR path, one of many pathways that are involved in aging.


Leave a Reply

Your email address will not be published. Required fields are marked *